BidaskClub lowered shares of Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) from a hold rating to a sell rating in a report published on Wednesday morning.
A number of other equities analysts have also commented on AUPH. Zacks Investment Research upgraded shares of Isotechnika Pharma from a sell rating to a hold rating in a research report on Wednesday, December 6th. ValuEngine upgraded shares of Isotechnika Pharma from a sell rating to a hold rating in a research report on Sunday, December 31st. Royal Bank of Canada started coverage on shares of Isotechnika Pharma in a research report on Thursday, February 8th. They issued an outperform rating and a $9.00 price target on the stock. Cantor Fitzgerald set a $16.00 price target on shares of Isotechnika Pharma and gave the company an overweight rating in a research report on Thursday, March 15th. Finally, Seaport Global Securities reaffirmed a buy rating and issued a $11.00 target price on shares of Isotechnika Pharma in a research note on Friday, March 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and an average target price of $10.93.
NASDAQ:AUPH opened at $5.15 on Wednesday. The stock has a market capitalization of $432.87, a price-to-earnings ratio of -5.60 and a beta of 2.26. Isotechnika Pharma has a 12 month low of $4.41 and a 12 month high of $8.19.
Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.10. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. Isotechnika Pharma had a negative net margin of 16,855.24% and a negative return on equity of 17.54%. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.11) earnings per share. equities research analysts predict that Isotechnika Pharma will post -0.7 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Spark Investment Management LLC bought a new position in shares of Isotechnika Pharma in the fourth quarter worth about $153,000. Wells Fargo & Company MN raised its stake in shares of Isotechnika Pharma by 13,197.5% in the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 26,395 shares during the last quarter. Cutler Capital Management LLC raised its stake in shares of Isotechnika Pharma by 25.0% in the fourth quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 10,000 shares during the last quarter. Swiss National Bank bought a new position in shares of Isotechnika Pharma in the fourth quarter worth about $421,000. Finally, Kazazian Asset Management LLC raised its stake in shares of Isotechnika Pharma by 11.6% in the fourth quarter. Kazazian Asset Management LLC now owns 156,126 shares of the biotechnology company’s stock worth $707,000 after acquiring an additional 16,189 shares during the last quarter. 28.50% of the stock is owned by institutional investors.
WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/isotechnika-pharma-auph-lowered-to-sell-at-bidaskclub.html.
About Isotechnika Pharma
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.
Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.